Skip to content

Structured Comprehensive Intervention to Stimulate Self- Management and Improve Quality of Life in COPD Patients

Effect of a Structured Comprehensive Intervention to Stimulate Self- Management and Improve Quality of Life in People With Chronic Obstructive Pulmonary Disease(COPD). A Randomised Clinical Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03762330
Enrollment
300
Registered
2018-12-03
Start date
2019-01-19
Completion date
2021-01-31
Last updated
2020-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

quality of life, self-management,, structured plan, COPD

Brief summary

This study evaluates the effect of of a structured self-management intervention plan in patients with chronic obstructive pulmonary disease in primary care setting.Half of the participants will receive the self-management plan while the other half will receive usual care.

Detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a great magnitude public health problem with an associated increased mortality and a high cost (consumption of health care resources and loss of health related quality of life (HRQoL)). The comprehensive approach to this complex disease, focusing self-care promotion, improves HRQoL and the patients clinical status, as shown by several studies, although further investigation is needed to confirm these results in the field of Primary Care (PC) and to formulate clear recommendations on the more effective type of intervention. Hypothesis: In (moderate-severe) COPD patients, a structured self-management intervention plan in the setting of primary care, is more effective than usual treatment on the main outcomes associated with the disease: HRQoL, lung function, exacerbations and hospital admissions, at 6, 12 and 24 months of follow-up. Objectives: To evaluate the impact of a comprehensive intervention plan to promote self-care and improve HRQoL in people with COPD in PC. Methods: Multicenter randomized controlled trial, conducted at PC centers in Barcelona. Determinations: Specific standardized and validated questionnaires, as the St George's Respiratory for the HRQoL. Statistical analysis: Intention to treat analysis. Descriptive statistics of the variables of the intervention and the control group to assess their homogeneity at the beginning of the study. An analysis of variance (ANOVA) will be used to assess differences among intervention groups. Expected results: A significant improvement in HRQoL attributable to the intervention performed in patients with COPD Applicability and Relevance: To implement the intervention plan in clinical practice and to standardize its content.

Interventions

BEHAVIORALCOPD structured self-management plan.

Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations

Sponsors

Institut Catala de Salut
CollaboratorOTHER_GOV
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with at least one visit at the primary care physician during the past year * Patients with a diagnosis of moderate (FEV1 50% - 80%) or severe (FEV1 30% - 50%) COPD * Patients treated with inhaled bronchodilators and accepting to participate in the study.

Exclusion criteria

* Patients unable to come to the primary care centre * Patients with cognitive impairment and/or a severe mental condition. * Patients with a diagnosis of asthma, tuberculosis or other chronic respiratory disease. * Patients needing chronic oxygen therapy. * Patients with any terminal disease

Design outcomes

Primary

MeasureTime frameDescription
Quality of life St. George´s Respiratory Questionnaire (SGRQ)Change from baseline at 6 ,12 and 24 monthsSt. George´s Respiratory Questionnaire (SGRQ).Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Number of items: 50 items Number of domains & categories : 2 parts (3 components). Part 1 : Symptoms component (frequency & severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Scaling of items Part I (Symptoms): several scales; Part II (Activity and Impacts): dichotomous (true/false) except last question (4-point Likert scale). Scores range from 0 to 100, with higher scores indicating more limitations.

Secondary

MeasureTime frameDescription
Dyspnea score severityChange from baseline at 6 ,12 and 24 monthsDyspnea severity assessed by the modified scale of the Medical Research Council (mMRC). Range 0-4 (none to maximum)
Changes in the Body mass index, Obstruction, Dyspnea, Exacerbations Index (BODEx index )Change from baseline at 6 ,12 and 24 monthsIndex including BMI (Body mass index), Obstruction, Dyspnea, Exacerbations. with possible answers from 0-3, each item. Range: 0-9. Mild: 0-2 Moderate: 3-4 Severe ≥5
Number of COPD exacerbationsat 6 ,12 and 24 months from baselineNumber of COPD exacerbations requiring a visit to primary care physician
Number of hospital admissions due to COPD exacerbationat 6 ,12 and 24 months from baselineNumber of hospital admissions due to COPD exacerbation
Changes in Anxiety and depression scalesChange from baseline at 6 ,12 and 24 monthsGoldberg's anxiety-depression scale (GADS): is an 18-item self-report symptom inventory that was developed by Goldberg and colleagues from 36 items in the Psychiatric Assessment Schedule. The GADS score is based on responses of 'yes' or 'no' to nine depression and nine anxiety items, asking how respondents have been feeling in the past month. Goldberg et al. (1988) considered patients with anxiety scores of 5 or more or with depression scores of 2 or more as having a 50% chance of a clinically important disturbance
Changes in forced vital capacity (FVC)Change from baseline at 6 ,12 and 24 monthsValue of FVC measured with forced spirometry
Changes in forced expiratory volume at the first second (FEV1)Change from baseline at 6 ,12 and 24 monthsValue of FEV1 measured with forced spirometry
Intensity of symptoms related to COPDChange from baseline at 6 ,12 and 24 monthsCOPD Assessment Test (CAT) : It consists of 8 questions with 5 possible answers valued from 0 to 5 (values close to 0: better health status)
Use of long-acting beta-adrenergic bronchodilator in monotherapyAt baseline and at 6 ,12 and 24 monthsUse of long-acting beta-adrenergic bronchodilator in monotherapy (yes or no)
Use of long-acting anticholinergic bronchodilator in monotherapyAt baseline and at 6 ,12 and 24 monthsUse of long-acting anticholinergic bronchodilator in monotherapy (yes or no)
Use of a double therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilatorAt baseline and at 6 ,12 and 24 monthsUse of a double therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilator (yes or no)
Use of a double therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilatorAt baseline and at 6 ,12 and 24 monthsUse of a double therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator (yes or no)
Use of a triple therapy of long-acting beta-adrenergic bronchodilator and long-acting anticholinergic bronchodilator plus inhaled steroidsAt baseline and at 6 ,12 and 24 monthsUse of a triple therapy of long-acting beta-adrenergic bronchodilator plus long-acting anticholinergic bronchodilator plus inhaled steroids (yes or no)
Use of a triple therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator plus inhaled steroidsAt baseline and at 6 ,12 and 24 monthsUse of a triple therapy of long-acting beta-adrenergic bronchodilator and short-acting anticholinergic bronchodilator plus inhaled steroids (yes or no)
Use of RoflumilastAt baseline and at 6 ,12 and 24 monthsUse of Roflumilast (yes or no)
Results of the Test of Adherence to Inhalers (TAI test)Change from baseline at 6 ,12 and 24 monthsTAI test. Includes 10 questions self-completed by patient. Range of each questions; 1worse compliance and 5 best compliance. The total score of the 10 items gives a total from 1-50.

Countries

Spain

Contacts

Primary ContactMaite Lopez Luque
tlopezl@gencat.cat93 326 89 01
Backup ContactPatricia Lloberes, Dr
plloberes@gmail.com+34 627906580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026